Earlier clinical studies have reported that cerivastatin has an antiatherosclerotic effect that is unique among the statins. In our study, human THP-1 macrophage cells were used to study the effects of various statins on the expressions of the atherosclerotic genes and Kruppel-like factor 2 (KLF2). Cerivastatin significantly inhibited the two atherosclerotic genes, monocyte chemoattractant protein-1 (MCP-1) and C-C chemokine receptor type 2 (CCR2) at both the mRNA and protein levels, while the other statins did not. Accordingly, cerivastatin was also the most potent inducer of KLF2 transcription in the macrophages. An siRNA-induced reduction in KLF2 expression blocked the inhibition of MCP-1 and CCR2 by cerivastatin. When the cells were further treated with mevalonate, farnesylpyrophosphate (FPP) or geranylgeranyl pyrophosphate (GGPP), the effects of cerivastatin on KLF2, MCP-1 and CCR2 were obviously reversed. Thus, the results showed that cerivastatin was a potent inhibitor of the inflammation genes MCP-1 and CCR2 through the induction of KLF2. The regulation of MCP-1, CCR2 and KLF2 by cerivastatin was isoprenoid pathway dependent. Our studies suggest that the effect of cerivastatin on atherosclerotic genes and KLF2 expression may contribute to the cardioprotection observed in reported clinical studies.
INTRODUCTION
The statin class of drugs has proven highly effective in the primary and secondary prevention of coronary artery disease [1] [2] [3] . The primary action of statins is the inhibition of 3-hydroxy-methylglutaryl coenzyme A (HMG-CoA) reductase. This inhibition leads to lower serum cholesterol [1] . Cholesterol lowering by statins is associated with a significant reduction in cardiovascular mortality [3, 4] . Clinical studies have shown that lipid lowering alone cannot explain the overall cardiovascular benefit of statins [5] [6] [7] . The non-lipid lowering activities of statins may be attributed to their pleiotropic effects on vascular function and inflammation. Statin treatment improves vascular function in vivo and modulates endothelial genes involved in vasomotor function, coagulation and inflammation [8, 9] . In addition, statins also reduce the production of some inflammatory cytokines in macrophages, a critical cell type in the development of atherosclerosis [10] . Clinical and experimental evidence show that not all statins produce similar effects on atherogenesis. In particular, whole heart scan score reversal studies have shown that cerivastatin decreased heart scores in patients, but other statins did not [11] [12] [13] . Achenbach et al. reported that the treatment of patients with coronary artery disease with 0.3 mg/day cerivastatin produced only an 8.8% increase in heart score as compared to a 25% increase in the control group without drug treatment [11] . Other studies with atorvastatin (80 mg) or pravastatin (40 mg) showed annual plaque growth similar to that seen in the control group regardless of the amount of LDL cholesterol reduction [12, 13] . Obtaining such startlingly different results with cerivastatin suggests that it may have unique anti-atherosclerotic activities. The differences in statin efficacy are likely due to their pleiotropic activity on the cells involved in atherosclerosis, including endothelial cells, smooth muscle cells and inflammatory cells such as macrophages [14] . Therefore, a better understanding of the action of cerivastatin on these cells is required. The transcription factor Kruppel-like factor 2 (KLF2) has emerged as an important atheroprotective gene. KLF2 is required for modulating endothelial function in vivo and in vitro [15, 16] . Statin-mediated expression of eNOS and thrombomodulin genes in endothelial cells requires KLF2 [15] . These genes are important for the maintenance of vasomotor tone and anti-thrombotic and antiinflammatory activities in the endothelium [15, 16] . In the ApoE-deficient mouse model of atherosclerosis, hemizygous deletion of KLF2 enhances atherosclerosis, indicating a direct atheroprotective role for KLF2 [17] . Overexpression of KLF2 inhibits pro-inflammatory genes such as VCAM-1 and enhances the expression of eNOS and thrombomodulin in endothelial cells [18] .
Although recent data show that the effect of statins on macrophage gene expression also involves KLF2 [19] , the understanding of the role of KLF2 in macrophages is limited.
MATERIALS AND METHODS

Materials
Cerivastatin was purchased from Medlogics. Lovastatin, atorvastatin, simvastatin and pravastatin were purchased from Sigma-Aldrich. Lipopolysaccharide (LPS), tumor necrosis factor-α (TNF-α), mevalonate, farnesylpyrophosphate (FPP) and geranylgeranylpyrophosphate (GGPP) were purchased from Sigma. Rabbit anti-human KLF2 and CCR2 antibodies were obtained from Abcam.
Cell culture THP-1 and U937 cells were obtained from the American Tissue Type Culture Collection (ATCC). Cells were maintained in RPMI-1640 (Mediatech) containing 10% fetal bovine serum (FBS; Sigma-Aldrich) and 1% penicillin/ streptomycin (Sigma-Aldrich), and incubated in a humidified incubator containing 5% CO 2 /95% air at 37ºC. In all of the experiments, cells were seeded at a concentration of 5 × 10 5 cells/ml in 12 well plates and then various statins were added to the medium. After 1 h, LPS at a final concentration of 100 ng/ml or TNF-α at a final concentration of 10 ng/ml was added to the cultures. After 24 h, supernatants were removed and assayed for MCP-1 levels. The cell pellets were collected for RNA and protein isolation.
Real-time RT-PCR analysis
Total RNA was extracted using the RNeasy Kit (Qiagen) according to the manufacturer's instructions. After reverse transcription using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems), PCR was performed using an ABI Prism 7500 Sequence Detection System (Applied Biosystems) and QuantiTect SYBR Green PCR Master Mix (Qiagen). All reactions were carried out in triplicate and the relative expression levels were calculated using the 2 -(ΔΔc(t)) method [20] . The expression of actin was used as an endogenous control in all experiments and relative fold changes were calculated. All data were expressed as the means ± standard deviation. The gene-specific forward and reverse primer sequences were: 5'-GATGAGATTGGCATGGC TTT-3' and 5'-GTCACCTTCACCGTTCCAGT-3' for actin; 5'-CCCCAGTC ACCTGCTGTTAT-3' and 5'-CAGATCTCCTTGGCCACAAT-3' for MCP-1; 5'-CTATCTGGGAGGGGTCTTCC-3' and 5'-ATGTTCGTCCTCCTCACAGG-3' for TNF-α; 5'-CCCATCATCTATGCCTTCGT-3' and 5'-ACTCCTGGACC TCCACACAC-3' for CCR2; and 5'-CACGATCCTCCTTGACGAGT-3' and 5'-TCTCACAAGGCATCACAAGC-3' for KLF2.
Measurement of MCP-1 in the cell supernatant
We used commercial ELISA kits (R&D Systems) to quantify MCP-1 in cell-free supernatants, according to the manufacturer's protocols. The absorbance at 450 nm and 570 nm (reference wavelength) was determined using a microplate reader (Synergy 2, Biotek). All of the experiments were performed in duplicate.
Western immunoblotting
Cells were rinsed twice with chilled PBS and then lysed with RIPA buffer (Sigma) supplemented with protease inhibitor cocktail (Thermo Scientific). Whole cell extracts were centrifuged at 12,000 rpm for 10 min to remove the insoluble material. The protein concentration in the supernatant was determined using a BCA Protein Assay Kit (Thermo Scientific). Equal amounts of protein (30 μg) for each sample were electrophoresed using polyacrylamide-SDS gels (Bio-Rad) and transferred via electro blotting onto PVDF membranes. Membranes were blocked for 1 h in 5% (w/v) non-fat dry milk before incubation with appropriate dilutions of anti-CCR2 or anti-KLF2 primary antibody and the corresponding secondary antibody. Blots were developed using the CL-XPosure System (Thermo Scientific). Quantification of the blots was performed with Image J software.
Transfection of KLF2 siRNA in THP-1 cells
We applied two different double-stranded small interfering RNA (siRNA) oligonucleotides targeting KLF2 from Ambion (5'-GGGCCUUAAUUUGUA CUGUTT-3' and 5'-ACAGUACAAAUUAAGGCCCTT-3') and two from Invitrogen (5'-CCUACACCAAGAGUUCGCAUCUGAA-3' and 5'-UUCA GAUGCGAACUCUUGGUGUAGG-3'). The negative control siRNA was obtained from Invitrogen. It was confirmed that the sequence of this siRNA did not show the off-target effect. THP-1 cells were seeded on 6-well plates at a density of 2 × 10 5 cells per well and treated with TNF-α (10 ng/ml) and cerivastatin (10 μM), then cultured at 37ºC overnight. After 24 h, the cells were transfected with 50 nM of either KLF2 or control siRNA for 24 h using Lipofectamin RNAiMAX Reagent (Invitrogen). The efficacy of gene silencing of KLF2 was determined via real time RT-PCR using a primer set specific for KLF2. After 24 h, statins and TNF-α were added as described before. The total RNA and protein were collected after a further 24 h.
Statistical analysis
All quantitative data were expressed as means ± standard deviation. Statistical analyses were performed using SPSS software. Statistical significance was determined using one-way analysis of variance (ANOVA) followed by a post hoc test.
RESULTS
The unique effect of cerivastatin on MCP-1 and CCR2 expression in THP-1 cells Statins have been shown to produce different effects on cytokine production in macrophages. Kuijk et al. showed that simvastatin synergistically enhanced LPS-induced IL-1β in THP-1 cells [21] . Other studies have shown the inhibition of MCP-1 expression by statins in monocytes [22, 23] . In this study, THP-1 cells were selected to investigate the effect of statins on MCP-1. As shown in Fig. 1A , stimulation of THP-1 cells with TNF-α highly induced MCP-1 mRNA expression. Studies had shown that simvastatin and atorvastatin stimulate endothelial responses in the 1-5 μM range. All statins at this concentration have also been shown to inhibit HMG-CoA reductase [24, 25] . In our study, we found that a 5 μM concentration of statins did not produce a significant effect on cell death, while higher concentrations of statins reduced cell viability (data not shown). Thus, 5 μM of each statin was chosen for the study. Interestingly, only cerivastatin inhibited the TNF-α-induced MCP-1, while other statins all significantly enhanced MCP-1 expression. Similar inhibition of MCP-1 was observed when U937 macrophages stimulated with LPS were treated with cerivastatin (data not shown). These results showed that cerivastatin was a potent regulator of MCP-1 expression in macrophages. The chemokine receptor of MCP-1, CCR2, plays a major role in macrophagemediated inflammation and atherosclerosis [26] . The effect of statins on CCR2 expression has not been well characterized. Examination of the effects of statins on CCR2 expression in THP-1 cells also showed that cerivastatin reduced the expression of CCR2. As shown in Fig. 1B , treatment with TNF-α under the conditions used in the previous experiments reduced CCR2 expression. Cerivastatin co-treatment further reduced CCR2 expression, resulting in almost 90% inhibition as compared to the basal levels, while other statins almost had no effect on CCR2 expression. The results suggest cerivastatin has a unique antiinflammatory effect on monocytes. Cerivastatin inhibits MCP-1 and CCR2 expression in a dose-dependent manner To further examine the anti-inflammatory effect of cerivastatin, different concentrations of cerivastatin were studied. TNF-α or LPS was used to induce inflammation. As shown in Fig. 2A , cerivastatin alone increased MCP-1 expression. With TNF-α or LPS induction, cerivastatin produced a small but significant enhancement of MCP-1 at low concentrations, while higher concentrations of cerivastatin inhibited the expression of MCP-1 in a dosedependent manner. Both the mRNA and protein levels of MCP-1 were significantly reduced at the highest concentration. The CCR2 mRNA and protein expressions kept decreasing with the increase in dose of cerivastatin. The inhibition effect became significant in the range of 5-10 μM. Fig. 3 . Cerivastatin is a potent inducer of KLF2 gene expression. A -Cells were incubated with 5 μM of cerivastatin (Cer), simvastatin (Sim), lovastatin (Lov) or atorvastatin (Ato) for 1 h and then stimulated with TNF-α (10 ng/ml) for 24 h. The KLF2 mRNA level was determined using real-time RT-PCR. B, C -Cells were incubated with the indicated concentrations of cerivastatin for 1 h and with or without TNF-α (10 ng/ml) treatment. The cells were incubated for 24 h before RNA extraction. The KLF2 mRNA level was determined using real-time RT-PCR (B). # Significant difference at p < 0.01 vs. non-treated group and * significant difference at p < 0.01 vs. TNF-α only group. Data represent the means ± SD of results from 3 experiments. The KLF2 protein level was determined by western blot analysis (C).
Cerivastatin induces KLF2 expression in THP-1 cells KLF2 has been found to more broadly affect immune cells, including T cells [27, 28] and B cells [29] . The effects of various statins on the expressions of macrophage KLF2 and its downstream atherogenic genes have not been well characterized. Thus different statins (5 μM) were used to stimulate KLF2 expression in THP-1. THP-1 cells express low levels of KLF2 in the absence of TNF-α or LPS. Treatment with TNF-α produced a minor increase in KLF2 mRNA (Fig. 3) . The addition of atorvastatin did not change the KLF2 level, while simvastatin and lovastatin increased the KLF2 expression 5-to 8-fold. Cerivastatin showed the strongest KLF2 induction, resulting in almost a 25-fold increase as compared to the basal levels (Fig. 3A) . Treatment of non-activated or TNF-α activated cells with different doses of cerivastatin produced a large and concentration-dependent induction of KLF2. At 10 μM, cerivastatin caused more than 50-fold induction of KLF2 mRNA (Fig. 3B) . The increase in mRNA paralleled a concentration-dependent increase in KLF2 protein (Fig. 3C) . The magnitude of KLF2 induction was much higher than reported for other inducers of KLF2. The results suggest the unique inhibitory effect of cerivastatin on MCP-1 and CCR2 might be KLF2 dependent.
Cerivastatin inhibits MCP-1 and CCR2 expression via KLF2
To confirm that MCP-1 and CCR2 inhibition by cerivastatin was KLF2 dependent, we inhibited the cerivastatin-mediated induction of KLF2 using small interfering RNA. As in previous experiments, THP-1 cells treated with TNF-α and cerivastatin were used as the baseline gene expression. Pretreatment with a control siRNA had almost no effect on KLF2 expression or the expression Fig. 4 . KLF2 siRNA reduced cerivastatin effect on MCP-1 and CCR2. THP-1 cells were treated with control siRNA or two different KLF2 specific siRNA for 24 h. Cells were then treated with 5 μM cerivastatin and 10 ng/ml TNF-α as in Fig. 1 . KLF2, MCP-1 and CCR2 mRNA levels were determined after 24 h. Data represent the mean ± SD of results from 3 experiments. *Significant difference at p < 0.01 vs. control siRNA group, # significant difference at p < 0.05 vs. control siRNA group. of MCP-1 and CCR2. Treatment with two different KLF2-specific siRNA resulted in about a 40-45% reduction in KLF2 levels as compared to the control siRNA group (Fig.4) . In the cultures treated with KLF2 siRNA, the expressions of both MCP-1 and CCR2 were enhanced about 1.5-to 2.5-fold (Fig. 4) . These results show that the reduction in KLF2 expression reversed the effect of cerivastatin and thus confirm that KLF2 is required for inhibition of MCP-1 and CCR2 gene expression.
The regulation of KLF2, MCP-1 and CCR2 by cerivastatin is dependent on isoprenoid metabolic pathways
To examine whether the effect of cerivastatin was dependent on the inhibition of isoprenoid generation, we treated THP-1 cells with either mevalonate (100 µM), FPP (10 µM) or GGPP (10 µM) and then with TNF-α (10 ng/ml) and cerivastatin (10 µM). As shown in Fig. 5A , mevalonate, FPP and GGPP all inhibited the induction of KLF2 by cerivastatin. GGPP was most effective, producing 100% reversal of cerivastatin stimulation. This result showed that cerivastatin upregulation of KLF2 in THP-1 cells was primarily through depletion of GGPP. To demonstrate that the inhibition of MCP-1 and CCR2 occurs through the isoprenoid pathway, we treated THP-1 cells with mevalonate, FPP and GGPP along with cerivastatin and TNF-α as in the experiments described for KLF2. As shown in Fig. 5B , TNF-α-stimulated MCP-1 was inhibited by cerivastatin. The addition of mevalonate and FFP reversed the inhibition of MCP-1 by cerivastatin. Interestingly, GGPP treatment produced 2-to 3-fold further stimulation of MCP-1 expression than that achieved with TNF-α alone. For the expression of CCR2, GGPP not only reversed the inhibition by cerivastatin, but also reversed the effect of TNF-α. These data suggest that the inhibition of CCR2 expression by TNF-α and cerivastatin is mediated through the isoprenoid pathway. The overexpression of CCR2 in the presence of GGPP suggests that the GGPP-dependent pathway limits the expression of MCP-1 and CCR2 in THP-1 cells.
DISCUSSION
According to reported clinical studies [11] [12] [13] , not all statins produce similar effects on atherogenesis. Cerivastatin decreased heart scores in patients but other statins did not [11] [12] [13] . Such different results with cerivastatin suggest that it may have unique anti-atherosclerotic activities. The differences in the efficacy of the various statins are likely due to their pleiotropic activity on the cells involved in atherosclerosis, including endothelial cells, smooth muscle cells and inflammatory cells such as macrophages [14] . In this study, cerivastatin was the only statin that inhibited the expression of the atherogenic genes MCP-1 and CCR2 in human THP-1 cells. The results also showed that cerivastatin exerted a biphasic effect on MCP-1 and CCR2 expression. Although biphasic effects are not commonly reported for statins, this may be an important pharmacological response. A biphasic effect on endothelial cell proliferation, migration, apoptosis and angiogenesis has been reported for cerivastatin and atorvastatin [30] . Other statins may also have a biphasic effect on MCP-1 and CCR2 expression, but they are not as potent as cerivastatin. They might need higher concentrations to exert an inhibitory effect that is also toxic and leads to cell death. At high but non-toxic concentrations, cerivastatin inhibited the expression of MCP-1 and CCR2 in THP-1 cells stimulated with TNF-α or LPS. To the best of our knowledge, these studies are first to show that CCR2 is a KLF2-modulated gene in macrophages. The transcription factor KLF2 has emerged as an important atheroprotective gene. It was identified as a shear stress response gene and initial studies focused on its role in regulation of endothelial function where it was found to modulate the expression of eNOS, thrombomodulin and inflammatory cytokines [15, 16] . More recently, KLF2 has been found to more broadly affect immune cells including T cells [27, 28] and B cells [29] . Bu et al. also reported that statininduced KLF2 expression in T cells reduced inflammatory responses [31] . However, only limited data exist on the regulation of KLF2 by statins in macrophages. In particular, the effects of different statins on the expression of macrophage KLF2 and its downstream atherogenic genes have not been well characterized. Thus, this investigation focused on KLF2 induction by cerivastatin, a statin that has been shown to exhibit greater cardioprotection than the other statins [11] [12] [13] . The understanding of the non-lipid-lowering activities of cerivastatin would help reveal its mechanism of atheroprotection and development of statins with greater direct beneficial effects on vascular disease. As found by Bu's et al. [31] , KLF2 expression had been upregulated by different statins. Our further studies showed that, among the statins tested, cerivastatin was the most potent and produced the highest stimulation of KLF2 gene expression. The biphasic effects of cerivastatin on KLF2 were also observed as changes in MCP-1 and CCR2 expression, which suggest that KLF2 might regulate the expression of MCP-1 and CCR2. Further siRNA knockdown experiments confirmed the requirement of KLF2 for inhibition of MCP-1 and CCR2 gene expression. Our studies show that although both mevalonate and FPP reversed the effect of cerivastatin, GGPP not only reversed it, but further stimulated the expression of MCP-1 and CCR2. Thus, it appears that the expression of the ligand and the receptor was coordinately regulated by isoprenoids. These data also suggest that either the other statins were unable to deplete GGPP levels as cerivastatin does or cerivastatin has additional activity to a drive greater activation of KLF2 and thus inhibition of CCR2 expression. KLF2 can modulate the transcription factors NF-κB and AP1. Evidence of a dose effect on KLF2 has been previously observed using lentiviral-mediated expression of KLF2 [19] . In that study, high KLF2 expression through lentivirus transfection produced a greater inhibition of MCP-1 as compared to statin alone. It may be that high KLF2 levels achieved using cerivastatin produce additional effects on these cells. We further confirmed the dependence of MCP-1 and CCR2 inhibition on KLF2 by demonstrating the enhancement of MCP-1 and CCR2 expression by KLF2-specific siRNA.
The understanding of the direct vascular protecting activities of statins is important. The recent JUPITER trial showed that in patients with low cholesterol (< 130 mg/dl) but high CRP-1, rosuvastatin significantly reduced cardiovascular events [32] . These and other studies show that reducing inflammation may further reduce cardiovascular risk. In this regard, a very intriguing finding exists on cerivastatin. The heart scan data reported by Achenbach et al. [11] showed that cerivastatin was unique in inhibiting plaque growth as compared to other statins [12, 13] . Our data showed that cerivastatin produced distinct effects on the expression of KLF2, a key atheroprotectant gene. High expression of KLF2 is expected to reduce macrophage recruitment, and a greater anti-atherosclerotic activity in patients with cardiovascular disease. Among the statins tested, cerivastatin effectively inhibited MCP-1 and CCR2 gene expression in stimulated macrophages. However, statins alone upregulated KLF2 expression but did not inhibit MCP-1 and CCR2 which suggest KLF2 might exert its inhibitory effect to inflammatory environment. This study has focused on KLF2 induction by cerivastatin in macrophages. Since statins exhibit pleiotropic activity on other cells involved in atherosclerosis namely, endothelial, smooth muscle cells and T cells, investigation of the effect of cerivastatin on KLF2 induction in these cells may shed important light on its atheroprotective role.
